EP300 and esophageal squamous cell carcinoma: Our functional and clinical analyses show that deletion of EP300 inhibits angiogenesis, hypoxia and EMT process, and high expression and mutation of EP300 correlates with poor prognosis, thus it may act as an oncogene in ESCC.